14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today DXCM ranks #19169 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$395.83 (-2.56%)

Volume: 929k

Closed: Jan 26, 2022

Hollow Logo Score: -5.364

DexCom Stock Forecast

$395.83 (-2.56%)

Volume: 929k

Closed: Jan 26, 2022

Score Hollow Logo -5.364

DexCom Company Profile

6340 Sequence Drive

San Diego CA 92121



Industry: Medical Devices

Sector: Healthcare



DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring; and DexCom G5 Mobile, a continuous glucose monitoring system. The company’s in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. It also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers; and sensor augmented insulin pumps. The company markets its products directly to endocrinologists, physicians, and diabetes educators. It has collaboration agreements with Animas Corporation and Tandem Diabetes Care, Inc. The company was founded in 1999 and is headquartered in San Diego, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE